$GH

Guardant Health, Inc.

Guardant Health develops blood and tissue tests, real-world data and AI analytics for cancer screening, disease monitoring and treatment selection. Its tests serve patients, clinicians and biopharmaceutical companies. Clinical products include Guardant360 tests for profiling advanced cancers, Guardant Reveal for residual disease, recurrence and therapy-response monitoring, and Shield for colorectal cancer screening in adults age 45 and older who are at average risk. Its biopharmaceutical offerings include GuardantINFINITY and GuardantOMNI tests, the GuardantINFORM data platform and GuardantConnect software for matching patients with clinical studies. These products use the company’s Smart Platform, which combines genomic, epigenomic and RNA-based data. Guardant Health sells tests to clinical customers through a U.S. sales organization and offers them internationally through direct contacts, distributors and laboratory partnerships. It also works with biopharmaceutical companies on testing, research, clinical studies and drug development, and provides analytical tools and data insights. Guardant Health is headquartered in Palo Alto, California.

AlphAI earnings readThird quarter 2026 · NOV 5Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
0
5
—
$28K
Azar Alex M II
100%
See all $GH insider activity →

Guardant Health, Inc. (GH): Entry into a Material Definitive Agreement

Guardant Health, Inc. (GH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032 PALO ALTO, Calif. November 11, 2026—(BUSINESS WIRE)—Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its inten

GH sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning GH (Guardant Health, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 5 bearish.

Recent GH coverage spans earnings, financial news and corporate actions.

In the last 30 days, GH insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($28K). The most active reporter was Azar Alex M II with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving GH

AlphAI scores every news story that mentions GH with an AI model for sentiment and relevance, and aggregates insider trades from Guardant Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GH

Score
$GHMedOffering· $500M · proposed

Guardant Health, Inc. (GH): Entry into a Material Definitive Agreement

Guardant Health, Inc. (GH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032 PALO ALTO, Calif. November 11, 2026—(BUSINESS WIRE)—Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its inten

Guardant Health adds five epigenomic cancer-testing tools

Guardant Health, Inc. (NASDAQ: GH) expanded its Guardant360 Liquid blood test with five new epigenomic applications for breast and lung cancer treatment decisions. The additions use its InfinityAI platform and target an oncology business that generated $231.3 million in Q3 revenue. The company did not disclose pricing or reimbursement changes. Shares closed at $155.35 on Nov. 10, predating the announcement.

$GHMedClinical / regulatory· FDA approval

Guardant360® Tissue Receives MOHW LDTS approval in Taiwan

Guardant Health (GH) announced its Guardant360® Tissue test received LDTS approval in Taiwan, paving the way for reimbursement. The test offers comprehensive tumor profiling with genomic and epigenomic insights, requiring less tissue than industry standards. This approval complements the Guardant360 test, approved in 2024, and expands patient access to precision oncology in Taiwan.

$GHHighAI 8/10

GH Q3 2026 deep dive: new product launches and coverage wins drive growth, but market cautious on profitability

GH reported Q3 2026 revenue of $361M, beating estimates by 2.9%, with adjusted EPS of -$0.29, beating by 7.8%. The company raised full-year revenue guidance to $1.37B. Growth was driven by Shield screening adoption, oncology product momentum, and Smart App launches. Cost improvements stabilized gross margins, but operating margins remained at -36.8%. Management expects continued growth from payer coverage expansions and product innovations, with cash flow breakeven targeted by 2027.

Guardant Health Inc (GH) (Q3 2026) Earnings Call Highlights: Revenue Surges 36%

Guardant Health (GH) reported a 36% revenue surge in Q3 2026. Free cash flow burn guidance increased to $205-$220M due to CMS delays. Non-GAAP operating expenses rose 26% to $287M. Shield ASP may decrease short-term due to patient mix shifts. Reveal Ultra launch is planned for year-end, but Medicare coverage is pending. The company faces reimbursement challenges for quarterly ESR1 testing.

Related tickers